DPP4 and Hypoglycemia: The studies have shown that the reduction in HbA1c was not different between DPP-4 inhibitors and thiazolidinediones, that adverse events, including rate of hypoglycemia, did not differ between the groups and that body weight was increased by thiazolidinedione therapy but not changed by DPP-4 inhibition.